Please login to the form below

Not currently logged in

Cell Therapeutics closes Zevalin buyout

Cell Therapeutics completes the USD 30m purchase of Biogen Idec's cancer drug, Zevalin

US-based biotechnology company Cell Therapeutics has completed the USD 30m purchase of Biogen Idec's cancer drug, Zevalin (90Y-ibritumomab tiuxetan).

In August 2007, Cell said it would buy US marketing, sales and development rights for the drug with a USD 10m upfront payment.

The deal also includes USD 20m in milestone payments when the drug is approved as an initial treatment for non-Hodgkin's lymphoma. It is already approved to treat patients who have relapsed after prior therapy.

Cell will pay royalties to Biogen based on Zevalin's net sales until at least December 2015. The company will pay royalties and share clinical trial costs with Bayer Schering, if studies are conducted outside the US, where Bayer Schering sells Zevalin.

On 27 December, Cell's shares rose USD 0.06 cents, or 3.2 per cent, to reach USD 1.91 in morning trading. Biogen's shares fell USD 0.33 to rest at USD 59.01.

FY06 sales of Zevalin were USD 16.4m.

2nd January 2008


Featured jobs

Subscribe to our email news alerts


Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...